Cytek Biosciences, Inc.
For the period ended Jun 10, 2026. Filed Apr 28, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 10, 2026 · Filed Apr 28, 2026
CTKB$5.83+8.0%Stored close · as of Nov 6, 2026
Contents
Pay-Versus-Performance Table
| Year · Summary Compensation Table Total for PEO(1) · Compensation Actually Paid to PEO(2) · Average Summary Compensation Table Total for Non-PEO NEOs(3) · Average Compensation Actually Paid to Non-PEO NEOs(4) · Value of Initial Fixed $100 Investment Based On: · Net Income(in thousands) · Company-Selected Measure -Revenue(7)(in thousands) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Total Shareholder Return(5) · Peer Group Total Shareholder Return(6) | ||||||||
| (a) | (b) | (c) | (d) | (e) | (f) | (g) | (h) | (i) |
| 2025 | $5,120,061 | $3,643,672 | $1,778,768 | $1,402,736 | $26.92 | $113.99 | ($66,539) | $201,493 |
| 2024 | $ 6,084,671 | $4,403,140 | $1,676,280 | $1,003,204 | $34.59 | $85.43 | ($6,020) | $200,453 |
| 2023 | $4,939,242 | $3,723,202 | $2,036,220 | $1,551,529 | $48.61 | $85.92 | ($12,148) | $193,015 |
| 2022 | $3,914,142 | $1,934,488 | $1,449,105 | $552,405 | $54.42 | $82.14 | $2,484 | $164,036 |
| 2021 | $4,818,502 | ($130,465) | $2,588,657 | $126,586 | $86.99 | $91.40 | $3,027 | $127,950 |
| (1) | The dollar amounts reported in column (b) represent the amount of total compensation reported for Wenbin Jiang, Ph.D., our Chief Executive Officer, for each covered year in the “Total” column of the Summary Compensation Table. Please refer to “Executive Compensation—Summary Compensation Table.” |
| (2) | The dollar amounts reported in column (c) represent the amount of “executive compensation actually paid” to Dr. Jiang, as computed in accordance with Item 402(v) of Regulation S-K for each covered year. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Dr. Jiang during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Dr. Jiang’s total compensation for each year to determine the executive compensation actually paid: |
| Year | ReportedSummary Compensation Table Total for PEO | ReportedValue of Equity Awards(a) | EquityAward Adjustments(b) | Compensation Actually Paid to PEO |
|---|---|---|---|---|
| 2025 | $5,120,061 | $4,000,000 | $2,523,611 | $3,643,672 |
| 2024 | $6,084,671 | $4,999,990 | $3,318,459 | $4,403,140 |
| 2023 | $4,939,242 | $4,000,000 | $2,783,961 | $3,723,202 |
| 2022 | $3,914,142 | $2,949,937 | $970,283 | $1,934,488 |
| 2021 | $4,818,502 | $4,250,000 | ($698,967) | ($130,465) |
| (a) | The grant date fair value of equity awards represents the total of the amounts reported in the “Stock Awards” and “Option Awards” columns in the Summary Compensation Table for each covered fiscal year. Please refer to “Executive Compensation—Summary Compensation Table.” |
|---|
| (b) | The equity award adjustments for each covered year include the addition (or subtraction, as applicable) of the following: (i) the year-end fair value of any equity awards granted in the covered year that are outstanding and unvested as of the end of the covered year; (ii) the amount equal to the change as of the end of the covered year (from the end of the prior year) in fair value of any equity awards granted in prior years that are outstanding and unvested as of the end of the covered year; (iii) for equity awards that are granted and vest in same covered year, the fair value as of the vesting date; (iv) for equity awards granted in prior years that vest in the covered year, the amount equal to the change as of the vesting date (from the end of the prior year) in fair value; and (v) for equity awards granted in prior years that are determined to fail to meet the applicable vesting conditions during the covered year, a deduction for the amount equal to the fair value at the end of the prior year. The amounts deducted or added in calculating the equity award adjustments are as follows: |
|---|
| Year | Year End Fair Value of Outstanding and Unvested Equity Awards Granted in Year | Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards | Fair Value as of Vesting Date of Equity Awards Granted and Vested in Year | Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in Year | Fair Value at End of Prior Year of Equity Awards that Failed to Meet Vesting Conditions in Year | Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation | TotalEquityAward Adjustments |
|---|---|---|---|---|---|---|---|
| 2025 | $3,740,952 | ($1,004,173) | $667,911 | ($881,080) | — | — | $2,523,611 |
| 2024 | $3,770,087 | ($718,741) | $748,652 | ($481,539) | — | — | $3,318,459 |
| 2023 | $2,725,385 | ($243,959) | $495,494 | ($192,959) | — | — | $2,783,961 |
| 2022 | $1,664,113 | ($920,384) | $575,505 | ($348,952) | — | — | $970,283 |
| 2021 | — | ($730,330) | — | $31,363 | — | — | ($698,967) |
| (3) | The dollar amounts reported in column (d) represent the average of the amounts of total compensation reported for our NEOs as a group (excluding Dr. Jiang, who has served as our PEO since 2014) for each covered year in the “Total” column of the Summary Compensation Table for each such year. Please refer to “Executive Compensation—Summary Compensation Table.” The names of each named executive officer (excluding Dr. Jiang) included for purposes of calculating the average amounts of total compensation in each covered year are as follows: (i) for 2025, William McCombe, our Chief Financial Officer, Ming Yan, Ph.D., our Chief Technology Officer, Valerie Barnett, our Chief Legal Officer and Corporate Secretary; Philippe Busque, Ph.D., our Senior Vice President, Global Sales and Services; (ii) for 2024, William McCombe, our Chief Financial Officer, Ming Yan, Ph.D., our Chief Technology Officer, Valerie Barnett, our Chief Legal Officer and Corporate Secretary; Philippe Busque, Ph.D., our Senior Vice President, Global Sales and Services; Patrik Jeanmonod, our former Chief Financial Officer, and Chris Williams, our former Chief Operating Officer; (iii) for 2023, Ming Yan, Ph.D., our Chief Technology Officer, Valerie Barnett, our Chief Legal Officer and Corporate Secretary; Patrik Jeanmonod, our former Chief Financial Officer, and Allen Poirson, Ph.D., our Senior Vice President, Business and Corporate Development; (iv) for 2022, Ming Yan, Ph.D., our Chief Technology Officer, and Valerie Barnett, our Chief Legal Officer and Corporate Secretary; and (v) for 2021, Ming Yan, Ph.D., our Chief Technology Officer, and Patrik Jeanmonod, our former Chief Financial Officer. |
| (4) | The dollar amounts reported in column (e) represent the average amount of “executive compensation actually paid” to our NEOs as a group (excluding Dr. Jiang), as computed in accordance with Item 402(v) of Regulation S-K for each covered fiscal year. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to our NEOs as a group (excluding Dr. Jiang) during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to the average total compensation for each year to determine the executive compensation actually paid, using the same methodology described above in Note 2(b): |
| Year | Average Reported Summary Compensation Table Total for Non-PEO NEOs | Average Reported Value of Equity Awards for Non-PEO NEOs | Average Equity Award Adjustments for Non-PEO NEOs(a) | Average Compensation Actually Paid to Non-PEO NEOs |
|---|---|---|---|---|
| 2025 | $1,778,768 | $1,162,500 | $786,468 | $1,402,736 |
| 2024 | $1,676,280 | $1,191,659 | $518,583 | $1,003,204 |
| 2023 | $2,036,220 | $1,462,500 | $977,809 | $1,551,529 |
| 2022 | $1,449,105 | $872,483 | ($24,217) | $552,405 |
| 2021 | $2,588,657 | $2,125,000 | ($337,071) | $126,586 |
| (a) | The amounts deducted or added in calculating the total average equity award adjustments are as follows: |
|---|
| Year | Year End Fair Value of Outstanding and Unvested Equity Awards Granted in Year | Year over Year Average Change in Fair Value of Outstanding and Unvested Equity Awards | Average Fair Value as of Vesting Date of Equity Awards Granted and Vested in Year | Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year | Average Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year | Average Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value | TotalAverageEquityAward Adjustments |
|---|---|---|---|---|---|---|---|
| 2025 | $1,087,217 | ($255,311) | $194,105 | ($239,544) | — | — | $786,468 |
| 2024 | $704,521 | ($154,267) | $140,569 | ($117,472) | ($54,767) | — | $518,583 |
| 2023 | $996,475 | ($110,740) | $181,155 | ($89,081) | — | — | $977,809 |
| 2022 | $492,194 | ($485,224) | $170,198 | ($201,386) | — | — | ($24,217) |
| 2021 | — | ($418,573) | — | $81,502 | — | — | ($337,071) |
| (5) | Cumulative total shareholder return is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our share price at the end and the beginning of the measurement period by our share price at the beginning of the measurement period. |
| (6) | Represents the weighted peer group total shareholder return, weighted according to the respective companies’ stock market capitalization at the beginning of each period for which a return is indicated. The peer group used for this purpose is the Nasdaq Biotechnology Total Return Index. The dollar amounts reported represent the amount of net income reflected in our audited financial statements for each covered year. |
| (7) | While we use numerous financial and non-financial performance measures for the purpose of evaluating performance for our executive compensation program, we have determined that revenue is the financial performance measure that, in our assessment, represents the most important performance measure (that is not otherwise required to be disclosed in the table) used by us to link compensation actually paid to Dr. Jiang and our other NEOs to our performance for the most recently completed year. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.